{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:21:31Z","timestamp":1768998091384,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Canadian Respiratory Research Network (CRRN)"},{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Tier 1 Canada Research Chair in COPD"},{"name":"Ulsan University Hospital (Biomedical Research Center Promotion Fund)","award":["10-03"],"award-info":[{"award-number":["10-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12931-017-0594-x","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T14:35:39Z","timestamp":1496154939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the Canadian Respiratory Research Network","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Won","family":"Ra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Chong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeni","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard J.","family":"Criner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prescott G.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Connett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilan K.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando J.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn D.","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. F. Paul","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"594_CR1","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","volume":"7","author":"A Agusti","year":"2012","unstructured":"Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483.","journal-title":"PLoS One"},{"key":"594_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1513\/AnnalsATS.201403-125OC","volume":"12","author":"SI Rennard","year":"2015","unstructured":"Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12:303\u201312.","journal-title":"Ann Am Thorac Soc"},{"key":"594_CR3","doi-asserted-by":"crossref","first-page":"e111228","DOI":"10.1371\/journal.pone.0111228","volume":"9","author":"MA Sze","year":"2014","unstructured":"Sze MA, Tsuruta M, Yang SW, Oh Y, Man SF, Hogg JC, et al. Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs. PLoS One. 2014;9:e111228.","journal-title":"PLoS One"},{"key":"594_CR4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1165\/rcmb.2015-0250PS","volume":"54","author":"RP Young","year":"2016","unstructured":"Young RP, Hopkins RJ, Marsland B. The gut-liver-lung axis. Modulation of the innate immune response and its possible role in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2016;54:161\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"594_CR5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/00365548.2014.989539","volume":"47","author":"F Wang","year":"2015","unstructured":"Wang F, Liu J, Zhang Y, Lei P. Association of Helicobacter pylori infection with chronic obstructive pulmonary disease and chronic bronchitis: a meta-analysis of 16 studies. Infect Dis (Lond). 2015;47:597\u2013603.","journal-title":"Infect Dis (Lond)"},{"key":"594_CR6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/thoraxjnl-2015-207059","volume":"70","author":"MA Sze","year":"2015","unstructured":"Sze MA, Chen YW, Tam S, Tashkin D, Wise RA, Connett JE, et al. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015;70:923\u20139.","journal-title":"Thorax"},{"key":"594_CR7","doi-asserted-by":"crossref","first-page":"G481","DOI":"10.1152\/ajpgi.00422.2001","volume":"283","author":"FS Lehmann","year":"2002","unstructured":"Lehmann FS, Terracciano L, Carena I, Baeriswyl C, Drewe J, Tornillo L, et al. In situ correlation of cytokine secretion and apoptosis in Helicobacter pylori-associated gastritis. Am J Physiol Gastrointest Liver Physiol. 2002;283:G481\u20138.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"594_CR8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1172\/JCI20925","volume":"113","author":"MJ Blaser","year":"2004","unstructured":"Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest. 2004;113:321\u201333.","journal-title":"J Clin Invest"},{"key":"594_CR9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.femsim.2004.10.013","volume":"44","author":"MM D\u2019Elios","year":"2005","unstructured":"D\u2019Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and cytokines: the \u201cdangerous liaisons\u201d. FEMS Immunol Med Microbiol. 2005;44:113\u20139.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"594_CR10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1128\/AAC.36.5.1133","volume":"36","author":"VG Loo","year":"1992","unstructured":"Loo VG, Sherman P, Matlow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992;36:1133\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"594_CR11","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.3748\/wjg.15.6102","volume":"15","author":"J Dong","year":"2009","unstructured":"Dong J, Yu XF, Zou J. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta-analysis. World J Gastroenterol. 2009;15:6102\u201310.","journal-title":"World J Gastroenterol"},{"key":"594_CR12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jac\/dkn007","volume":"61","author":"BS Murphy","year":"2008","unstructured":"Murphy BS, Sundareshan V, Cory TJ, Hayes Jr D, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. J Antimicrob Chemother. 2008;61:554\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"594_CR13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7150\/ijbs.5.667","volume":"5","author":"K Yamauchi","year":"2009","unstructured":"Yamauchi K, Shibata Y, Kimura T, Abe S, Inoue S, Osaka D, et al. Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages. Int J Biol Sci. 2009;5:667\u201378.","journal-title":"Int J Biol Sci"},{"key":"594_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-8579(98)00091-0","volume":"11","author":"AA Khan","year":"1999","unstructured":"Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents. 1999;11:121\u201332.","journal-title":"Int J Antimicrob Agents"},{"key":"594_CR15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689\u201398.","journal-title":"N Engl J Med"},{"key":"594_CR16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0140-6736(92)90929-W","volume":"339","author":"TU Kosunen","year":"1992","unstructured":"Kosunen TU, Seppala K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet. 1992;339:893\u20135.","journal-title":"Lancet"},{"key":"594_CR17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/1998\/303628","volume":"12","author":"CA Fallone","year":"1998","unstructured":"Fallone CA, Loo VG, Barkun AN. Utility of serology in determining Helicobacter pylori eradication after therapy. Can J Gastroenterol. 1998;12:117\u201324.","journal-title":"Can J Gastroenterol"},{"key":"594_CR18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1183\/09031936.00140613","volume":"43","author":"PG Woodruff","year":"2014","unstructured":"Woodruff PG, Chatila W, Connett JE, Criner GJ, Curtis JL, Dransfield MT, et al. Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial. Eur Respir J. 2014;43:295\u20138.","journal-title":"Eur Respir J"},{"key":"594_CR19","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An introduction to the bootstrap","author":"B Efron","year":"1993","unstructured":"Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993."},{"key":"594_CR20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-155-3-201108020-00008","volume":"155","author":"A Qaseem","year":"2011","unstructured":"Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179\u201391.","journal-title":"Ann Intern Med"},{"key":"594_CR21","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of Chronic Obstructive Lung Disease. updated 2016. \nhttp:\/\/www.goldcopd.org\n\n. Accessed 1 May 2017."},{"key":"594_CR22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1164\/rccm.201402-0207OC","volume":"189","author":"MK Han","year":"2014","unstructured":"Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"594_CR23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/aje\/kwr288","volume":"175","author":"YH Grad","year":"2012","unstructured":"Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race\/ethnic disparities. Am J Epidemiol. 2012;175:54\u20139.","journal-title":"Am J Epidemiol"},{"key":"594_CR24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/jech.54.6.444","volume":"54","author":"S Rosenstock","year":"2000","unstructured":"Rosenstock S, Jorgensen T, Andersen L, Bonnevie O. Seroconversion and seroreversion in IgG antibodies to Helicobacter pylori: a serology based prospective cohort study. J Epidemiol Community Health. 2000;54:444\u201350.","journal-title":"J Epidemiol Community Health"},{"key":"594_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0140-6736(93)91473-Y","volume":"342","author":"EJ Kuipers","year":"1993","unstructured":"Kuipers EJ, Pena AS, van Kamp G, Uyterlinde AM, Pals G, Pels NF, et al. Seroconversion for Helicobacter pylori. Lancet. 1993;342:328\u201331.","journal-title":"Lancet"},{"key":"594_CR26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0016-5085(92)91782-Y","volume":"102","author":"J Parsonnet","year":"1992","unstructured":"Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology. 1992;102:41\u20136.","journal-title":"Gastroenterology"},{"key":"594_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/515376","volume":"178","author":"T Kumagai","year":"1998","unstructured":"Kumagai T, Malaty HM, Graham DY, Hosogaya S, Misawa K, Furihata K, et al. Acquisition versus loss of Helicobacter pylori infection in Japan: results from an 8-year birth cohort study. J Infect Dis. 1998;178:717\u201321.","journal-title":"J Infect Dis"},{"key":"594_CR28","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1017\/S0950268814003938","volume":"143","author":"WS Krueger","year":"2015","unstructured":"Krueger WS, Hilborn ED, Converse RR, Wade TJ. Environmental risk factors associated with Helicobacter pylori seroprevalence in the United States: a cross-sectional analysis of NHANES data. Epidemiol Infect. 2015;143:2520\u201331.","journal-title":"Epidemiol Infect"},{"key":"594_CR29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hel.12043","volume":"18","author":"JH Jung","year":"2013","unstructured":"Jung JH, Choi KD, Han S, Jung HY, Do MY, Chang HS, et al. Seroconversion rates of Helicobacter pylori infection in Korean adults. Helicobacter. 2013;18:299\u2013308.","journal-title":"Helicobacter"},{"key":"594_CR30","first-page":"1793","volume":"89","author":"WM Wang","year":"1994","unstructured":"Wang WM, Chen CY, Jan CM, Chen LT, Perng DS, Lin SR, et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994;89:1793\u20136.","journal-title":"Am J Gastroenterol"},{"key":"594_CR31","first-page":"85","volume":"91","author":"AF Cutler","year":"1996","unstructured":"Cutler AF, Prasad VM. Long-term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol. 1996;91:85\u20138.","journal-title":"Am J Gastroenterol"},{"key":"594_CR32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/00365540410021063","volume":"37","author":"I Daugule","year":"2005","unstructured":"Daugule I, Rumba I, Ejderhamn J. Previous antibacterial treatment due to concomitant infections in preschool children is associated with a lower Helicobacter pylori positivity. Scand J Infect Dis. 2005;37:326\u20139.","journal-title":"Scand J Infect Dis"},{"key":"594_CR33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF02962382","volume":"26","author":"W Dohmen","year":"1998","unstructured":"Dohmen W, Seelis RE. The role of azithromycin in the treatment of Helicobacter pylori infection - a retrospective report. Infection. 1998;26:256\u201362.","journal-title":"Infection"},{"key":"594_CR34","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1473-3099(06)70627-2","volume":"6","author":"MM Gerrits","year":"2006","unstructured":"Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6:699\u2013709.","journal-title":"Lancet Infect Dis"},{"key":"594_CR35","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, Atherton J, Axon AT, Bazzoli F, et al. Management of Helicobacter pylori infection--the Maastricht IV\/ Florence Consensus Report. Gut. 2012;61:646\u201364.","journal-title":"Gut"},{"key":"594_CR36","first-page":"760","volume":"73","author":"RM Peek Jr","year":"1995","unstructured":"Peek Jr RM, Miller GG, Tham KT, Perez-Perez GI, Zhao X, Atherton JC, et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 1995;73:760\u201370.","journal-title":"Lab Invest"},{"key":"594_CR37","first-page":"290","volume":"31","author":"F Perri","year":"1999","unstructured":"Perri F, Clemente R, Festa V, De Ambrosio CC, Quitadamo M, Fusillo M, et al. Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies. Ital J Gastroenterol Hepatol. 1999;31:290\u20134.","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"594_CR38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1081\/IPH-100102563","volume":"23","author":"F Russo","year":"2001","unstructured":"Russo F, Jirillo E, Clemente C, Messa C, Chiloiro M, Riezzo G, et al. Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori (H. pylori). Immunopharmacol Immunotoxicol. 2001;23:13\u201324.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"594_CR39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1164\/ajrccm.153.2.8564092","volume":"153","author":"VM Keatings","year":"1996","unstructured":"Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"594_CR40","doi-asserted-by":"crossref","first-page":"50s","DOI":"10.1183\/09031936.01.00229701","volume":"34","author":"KF Chung","year":"2001","unstructured":"Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2001;34:50s\u20139.","journal-title":"Eur Respir J Suppl"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-017-0594-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T07:51:06Z","timestamp":1498809066000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-017-0594-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1186\/s12931-017-0594-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]},"article-number":"109"}}